Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Medifast's (MED) Q4 results reflect the impacts of poor customer acquisition. However, it is showing resilience, banking on its strategic focus on medically supported weight loss, indicating potential for growth.

Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y

Medifast, Inc. (MED) Q4 2023 Earnings Call Transcript

Medifast (MED) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $3.70 per share a year ago.

Medifast (MED) Q4 Earnings and Revenues Surpass Estimates

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Revenue of $191.0 million, with revenue per active earning Coach of $4,648 Independent active earning OPTAVIA Coaches of 41,100 Net income of $6.0 million (non-GAAP adjusted net income of $11.9 million) Earnings per diluted share ("EPS") o.

Medifast Announces Fourth Quarter and Full Year 2023 Financial Results

Cementos Pacasmayo

Devon Energy

Enbridge

Energy Transfer LP Unit

Euronav

FS KKR Capital Corp

Golub Capital BDC

HSBC Holdings

Kinder Morgan

Dorian LPG

Altria

Petroleo Brasileiro

Solaris Oilfield Infrastructure

Sociedad Quimica Y Minera De Chile

Trimble

TORM

Vale S.A.

Large Cap Value is a value ranking strategy that looks at the price of a stock relative to measurements of intrinsic firm value. The Ben Graham Formula strategy selects ultra-stable stocks based on a screen in Graham's book, "The Intelligent Investor." 54 out of 69 All-Star-Value Dividend stocks offer annual dividends exceeding their price per share.

54 Ideal Value Dogs For February

Agree Realty

Bristol-Myers

OGE Energy

ONEOK

Vici Properties

Every month we look at companies that are delivering not only a solid dividend yield but also showing a trend of growing dividends. Companies that can consistently deliver dividend growth due to rising earnings can generate long-term wealth. February 2024's dividend screening article gives us a look at some familiar names but two new names we haven't discussed before.

February's 5 Dividend Growth Stocks With 4.75%+ Yields

Medifast's (MED) fourth-quarter results are likely to reflect the impacts of macroeconomic challenges like inflation, while key growth initiatives like innovation bode well.

Medifast (MED) Q4 Earnings Coming Up: What Should You Know?

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, February 20, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chie.

Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2023

Frontline

Nu Skin Enterprises

Omega Healthcare Investors

PennantPark Floating Rate Capital

We decided to screen our 24/7 Wall St. dividend research database for companies that pay gigantic dividends that investors have likely never heard of.

5 Stocks You Have Never Heard of Pay Massive Dividends

Ares Capital

British American Tobacco

MPLX

OneMain Hld

This company is a high-yielding Business Development Company (BDC) paying a massive 9.41% dividend.

7 ‘Strong Buy' Ultra Dividend Leaders To Grab Before It's Too Late

Plains All American Pipeline

Investors love dividend stocks because they provide dependable income and give investors a great opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time. In other words, the actual investment or portfolio return consists of income and stock appreciation.

5 High-Yield Dividend Stocks With Double Digit Upside, According to Wall Street

Medifast's (MED) focus on combining lifestyle coaching with innovative health solutions and targeting diverse markets bode well amid challenges in customer acquisition and high costs.

Medifast's (MED) Holistic Health Solution, Innovation Bode Well

Artisan Partners Asset Management

Broadstone Net Lease

DHT Holdings

Hess Midstream Partners

Innovative Industrial Properties

LyondellBasell Industries

Manulife Financial

National Retail Properties

NETSTREIT Corp

Realty Income Corp

Philip Morris

Southern Copper

Western Union

Dividend growth stocks can provide reliable cash flows and long-term wealth to income investors. In this monthly publication, we screen dividend stocks based on safety, growth, and consistency, which are important for income investors. The five dividend stocks we are touching on today are Altria, Philip Morris International, Manulife Financial Corp., LyondellBasell Industries N.V., and NETSTREIT Corp.

December's 5 Dividend Growth Stocks With 5.10%+ Yields

LifeMD 

LifeMD Inc. NASDAQ: LFMD is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing with no health insurance required.

LifeMD expands telehealth GLP-1weight-loss service with Medifast

Big 5 Sporting Goods

B&G Foods

FAT Brands

Guess?

Icahn Enterprises

Kronos Worldwide

As the markets soar higher following the Federal Reserve's latest decision on interest rates, now may be a great time to jettison any dividend stocks to sell from your portfolio. While stocks overall could continue to perform strongly, company-specific factors can result in poor or even negative returns with many high-yield but low-quality dividend plays.

7 Dividend Stocks I Wouldn't Touch With a 10-Foot Pole

High returns on capital typically generate substantial value for long-term investors over extended periods. Businesses yielding high returns often command premium valuations in the market.

Potential 300% Upside: Uncovering Medifast's Investment Opportunity

Medifast (MED) penetrates the medically supported weight loss market via a collaboration with LifeMD, Inc. (LFMD). The company discontinues quarterly cash dividends.

Medifast (MED) Collaborates With LifeMD, Discontinues Dividend

Medifast partners with LifeMD to offer virtual weight management program with access to GLP-1 drugs. Medifast invests $20 million in LifeMD, with $10 million represented by common stock purchase. Survey shows over 40% of people with BMI greater than 27 are interested in prescription weight loss medication.

LifeMD: Medifast Partnership Further Validates Weight Management Program

LifeMD Inc (NASDAQ:LFMD) stock traded higher in Wednesday's early trade, up 11% to $8.99, as the health company announced an agreement with Medifast Inc (NYSE:MED), which sees the new partners working to develop a clinically supported weight management program, featuring GLP-1 medications. GLP-1 (glucagon-like peptide 1) based drugs – which include Novo Nordisk (NYSE:NVO)'s Ozempic -have quickly been adopted as something of a ‘blockbuster' for obesity and weight loss treatments, among an emerging list of other ailments.

LifeMD shares rise on Medifast deal for new GLP supported weight loss programmes

The companies are teaming up to offer a ‘transformative weight management solution.'

LifeMD Stock Pops on Medifast Agreement. It's All About Weight-Loss Drugs.

LifeMD Inc.'s stock LFMD, +1.76% soared 9% early Wednesday, after the virtual primary care provider said it's teaming up with Medifast Inc. MED, +1.03%, a wellness company known for its habit-based and coach-guided lifestyle service Optavia, to create a clinically supported weight management program that will include the new class of weight-loss drugs called GLP-1. The drugs developed by Eli Lilly & Co. LLY, +0.12% and Denmark's Novo Nordisk NVO, -0.46% NOVO.B, +1.18% are named after a gut hormone that they mimic to control blood sugar have become highly popular and have even suffered shortages in the past year.

LifeMD's stock soars 9.5% on news company is teaming up with Medifast to create weight-management program that includes GLP-1 drugs

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today launched the first phase of its business transformation, as part of its commitment to providing comprehensive health and wellness solutions to customers across the United States. The company will expand into the medically supported weight loss market through a collaboration with LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual.

Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, a Virtual Primary Care Provider, and Adjusting its Capital Allocation Policy

Collaboration will integrate LifeMD's telehealth platform and GLP-1 offering for medically qualified patients with OPTA VIA Coach-guided, healthy lifestyle solution

LifeMD and Medifast Partner to Offer Transformative Weight Management Solution

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Why Is Medifast (MED) Down 1.1% Since Last Earnings Report?

Best Buy

Deluxe

Medical Properties Trust

Walgreens

Xerox

As 2023 comes to a close, now may be a great time to figure out which stocks to sell. If you are an income-focused investor, this may entail figuring out the top dividend stocks to sell.

7 Doomed Dividend Stocks to Sell in December

News for Medifast Stock (MED)